HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction.

Abstract
Since the anti-epileptic drug Zonisamide (ZNS) seems to exert beneficial effects in Parkinson's (PD) disease, we have investigated the electrophysiological effects of ZNS in a rat corticostriatal slice preparation. ZNS affected neither the resting membrane potential nor the input resistance of the putative striatal spiny neurons. In contrast, this drug depressed in a dose-dependent manner the current-evoked repetitive firing discharge with a EC(50) value of 16.38 microM. ZNS also reduced the amplitude of glutamatergic excitatory postsynaptic potentials (EPSPs) with a EC(50) value of 32.5 microM. Reduced activity of the mitochondrial respiratory chain, particularly complex I and II, is implicated in the pathophysiology of PD and Huntington's (HD) diseases, respectively. Thus, ZNS was also tested in two different in vitro neurotoxic models obtained by acutely exposing corticostriatal slices either to rotenone, a selective inhibitor of mitochondrial complex I, or to 3-nitropropionic acid (3-NP), an inhibitor of complex II. Additionally, we also investigated the effect of ZNS in an in vitro model of brain ischemia. Interestingly, low concentrations of ZNS (0.3, 1, 3 and 10 microM) significantly reduced the rotenone-induced toxicity protecting striatal slices from the irreversible loss of corticostriatal field potential (FP) amplitude via a GABA-mediated mechanism. Conversely, this drug showed no protection against 3-NP and ischemia-induced toxicity. Our data indicate that relatively high doses of ZNS are required to decrease striatal neuronal excitability while low concentrations of this drug are sufficient to protect striatum against mitochondrial impairment suggesting its possible use in the therapy of basal ganglia neurodegenerative diseases.
AuthorsCinzia Costa, Alessandro Tozzi, Elisa Luchetti, Sabrina Siliquini, Vincenzo Belcastro, Michela Tantucci, Barbara Picconi, Riccardo Ientile, Paolo Calabresi, Francesco Pisani
JournalExperimental neurology (Exp Neurol) Vol. 221 Issue 1 Pg. 217-24 (Jan 2010) ISSN: 1090-2430 [Electronic] United States
PMID19913015 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antioxidants
  • Enzyme Inhibitors
  • GABA Antagonists
  • Isoxazoles
  • Nitro Compounds
  • Propionates
  • Uncoupling Agents
  • Rotenone
  • Glutamic Acid
  • Zonisamide
  • Glucose
  • 3-nitropropionic acid
  • Bicuculline
Topics
  • Action Potentials (drug effects)
  • Animals
  • Antioxidants (pharmacology)
  • Bicuculline (pharmacology)
  • Corpus Striatum (cytology)
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (toxicity)
  • Excitatory Postsynaptic Potentials (drug effects)
  • GABA Antagonists (pharmacology)
  • Glucose (deficiency)
  • Glutamic Acid (pharmacology)
  • In Vitro Techniques
  • Isoxazoles (pharmacology)
  • Male
  • Neurons (drug effects)
  • Nitro Compounds (toxicity)
  • Propionates (toxicity)
  • Rats
  • Rats, Wistar
  • Rotenone (toxicity)
  • Uncoupling Agents (pharmacology)
  • Zonisamide

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: